Four to buy
Genus
The pig division of this global animal-genetics firm enjoyed record operating profits in the year to 30 June, while its proprietary breeding lines give it a leading market position. Genus is now close to commercialising a “game changing” gene-editing platform that should allow farmers to breed pigs that are resistant to PRRS (porcine reproductive and respiratory syndrome), an illness that costs the industry billions of dollars a year globally. The shares are a long-term
